C12N 2800/204
Of bacterial origin
Official title: of bacterial origin, e.g. BAC
C12N2800/204 (Of bacterial origin) appears on 159 US grants and 256 published applications in this corpus.
Search patents in C12N- Granted patents
- 159
- Published applications
- 256
- Assignees
- 106
- Inventors
- 293
- Latest grant
- 7 Jul 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1997 | 1 | 0 |
| 1998 | 0 | 0 |
| 1999 | 2 | 0 |
| 2000 | 3 | 0 |
| 2001 | 1 | 0 |
| 2002 | 4 | 7 |
| 2003 | 9 | 7 |
| 2004 | 2 | 15 |
| 2005 | 2 | 13 |
| 2006 | 4 | 8 |
| 2007 | 2 | 7 |
| 2008 | 5 | 6 |
| 2009 | 8 | 7 |
| 2010 | 4 | 10 |
| 2011 | 1 | 11 |
| 2012 | 1 | 5 |
| 2013 | 2 | 17 |
| 2014 | 7 | 27 |
| 2015 | 2 | 9 |
| 2016 | 14 | 8 |
| 2017 | 9 | 10 |
| 2018 | 15 | 8 |
| 2019 | 12 | 16 |
| 2020 | 12 | 11 |
| 2021 | 9 | 15 |
| 2022 | 7 | 8 |
| 2023 | 7 | 9 |
| 2024 | 5 | 8 |
| 2025 | 5 | 10 |
| 2026 | 4 | 4 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- VHH-containing heavy chain antibody and production thereof7 Jul 2026US 12,673,984 B2Universitätsklinikum Hamburg-Eppendorf
- Humanized universal light chain mice19 May 2026US 12,628,801 B2Regeneron Pharmaceuticals, Inc.
- Genetically modified T cell receptor mice24 Mar 2026US 12,582,105 B2Regeneron Pharmaceuticals, Inc.
- Non-human animals expressing pH-sensitive immunoglobulin sequences10 Feb 2026US 12,543,711 B2Regeneron Pharmaceuticals, Inc.
- Recombinant cytomegalovirus vectors as vaccines for tuberculosis14 Oct 2025US 12,442,018 B2International AIDS Vaccine Initiative
- Genetically modified t cell receptor mice4 Jun 2026US 2026/0150821 A1Regeneron Pharmaceuticals, Inc.
- Humanized light chain mice7 May 2026US 2026/0123612 A1Regeneron Pharmaceuticals, Inc.
- Tcd34 And Other Markers For Identification And Sorting Of Cells And For Use As In Vivo Tracking Assistant7 May 2026US 2026/0125691 A1CarryGenes Bioengineering, LLC
- Non-Human Animals Expressing pH-Sensitive Immunoglobulin Sequences23 Apr 2026US 2026/0107928 A1Regeneron Pharmaceuticals, Inc.
- Common light chain mouse25 Dec 2025US 2025/0386809 A1Regeneron Pharmaceuticals, Inc.
Most cited
By later US patents
- Methods of modifying eukaryotic cells420US 6,596,541 B2Regeneron Pharmaceuticals, Inc. · 2003
- Methods of modifying eukaryotic cells171US 8,502,018 B2Regeneron Pharmaceuticals, Inc. · 2013
- ADAM6 mice83US 8,642,835 B2Regeneron Pharmaceuticals, Inc. · 2014
- ADAM6 mice75US 8,697,940 B2Regeneron Pharmaceuticals, Inc. · 2014
- Hybrid antibodies comprising human variable regions and mouse constant regions produced in a genetically modified mouse60US 8,791,323 B2Regeneron Pharmaceuticals, Inc. · 2014